SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Thread II -- Ignore unavailable to you. Want to Upgrade?


To: SpinCity1 who wrote (2518)6/22/2001 11:02:29 AM
From: SpinCity1  Respond to of 9026
 
MRK sales went to PHA I do believe...
Merck said Vioxx sales may fall short of the top of the
given range because the class of drugs -- called COX-2
inhibitors -- that Vioxx helped pioneer is not penetrating the
market for analgesics and arthritis as quickly as expected.
That class of drugs includes Pharmacia Corp.'s <PHA.N>
blockbuster Celebrex.